HEMATOLOGY

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

A dual-target PI3 kinase inhibitor demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.

Jennifer Woyach, MD, discusses Bruton's tyrosine kinase inhibition and the mechanism of action of ibrutinib.

Julian Adams, PhD, from Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes how T-rapa cells work.

Adding the BTK inhibitor ibrutinib to standard rituximab (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100%.

Ibrutinib was well tolerated and highly effective in eradicating tumor cells in both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia.

Two DNA demethylation biomarkers could potentially be used to more accurately determine response to epigenetic drugs for myelodysplastic syndromes.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

The FDA has received a new drug application for ibrutinib as a therapy for previously treated CLL and previously treated MCL.

The recent approval of the second-generation proteasome inhibitor carfilzomib by the FDA comes nine years after the initial approval of bortezomib, the first-in-class drug of its type.

Edward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.

Patients with chronic lymphocytic leukemia (CLL) and patients with mantle cell lymphoma (MCL) showed high response rates to therapy with ibrutinib.

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone showed efficacy in patients with previously treated multiple myeloma.

A phase I study found that idelalisib produced rapid and prolonged tumor shrinkage in half of patients with relapsed or refractory CLL who received the drug as monotherapy.

Lenalidomide has been approved to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

Working in a laboratory at the National Institutes of Health, Benjamin W. Purow, MD, became the first researcher to demonstrate that the Notch pathway plays a role in gliomas.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.

The American Association for Cancer Research is an annual showcase of the latest scientific cancer research, with updates on phase I, often first-in-human clinical trials.

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.

While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.

A phase III study of inotuzumab ozogamicin for patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy was halted after a scheduled interim analysis.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.

Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, describes the mechanism of action of antibody drug conjugates and their use.

Acute myeloid leukemia (AML), the most common acute form of leukemia in adults, is potentially driven by at least one genetic mutation in nearly all cases.